All Wales Medicines Strategy Group

Grŵp Strategaeth Meddyginiaethau Cymru Gyfan

Final Appraisal Recommendation

Alteplase (Actilyse® Cathflo® 2 mg)

Limited submission by:
Boehringer Ingelheim Ltd

Advice No: 1911 – December 2011

Recommendation of AWMSG

Alteplase (Actilyse® Cathflo® 2 mg) is recommended as an option for use within NHS Wales for the thrombolytic treatment of occluded central venous access devices including those used for haemodialysis.

AWMSG is of the opinion that alteplase (Actilyse® Cathflo® 2 mg) is not suitable for shared care within NHS Wales.

Additional notes:
This recommendation applies only to the use of alteplase 2 mg vial (Actilyse® Cathflo® 2 mg) for the indication under consideration. The alteplase 2 mg vial (Actilyse® Cathflo® 2 mg) is the only presentation of alteplase licensed for use in this indication.

Alteplase (Actilyse® Cathflo® 2 mg) for the above indication met the following criteria for eligibility for a limited submission:

- New formulation with a pro-rata or lower cost per treatment.
- Anticipated usage in NHS Wales is considered to be of minimal budgetary impact.

In reaching this recommendation AWMSG took account of the AWMSG Secretariat Assessment Report, the preliminary appraisal recommendation (PAR) and the applicant company's response to the PAR, lay perspective and discussions at AWMSG.

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as: